The Continuous Single Culture®-NX (CSCM-NX) is intended for use as a culture medium for human gametes and embryos from fertilization through day 5/6 of development in vitro.

Device Description

The Continuous Single Culture®-NX (CSCM-NX) is a culture medium using a formulation modified from the predicate device. It is intended for culture of embryos from fertilization to blastulation. This medium consists of salts, energy substrates, amino acids, buffering agents, nutrients supplements, and antibiotics. This product is a single-use device supplied in a fill volume of 20 mL and 60 mL. It is aseptically filled into sterilized bottles and has a sterility assurance level (SAL) of 10⁻⁶. The product is tested for pH, osmolality, embryotoxicity, spermtoxicity, endotoxin, and sterility before lot release. The product has a four-month shelf-life and remains stable for four weeks after opening/closing of the bottle when it is stored at 2-8°C.

AI/ML Overview

This document describes the Continuous Single Culture®-NX (CSCM-NX), a culture medium for human gametes and embryos. The information provided is from a 510(k) premarket notification.

Acceptance Criteria and Reported Device Performance

The acceptance criteria and reported device performance are primarily focused on ensuring the new device (CSCM-NX) performs comparably to its predicate device (Continuous Single Culture Complete) and meets safety and quality standards for reproductive media.

Table of Acceptance Criteria and Reported Device Performance:

Characteristic	Acceptance Criteria (from predicate device)	Reported Device Performance (CSCM-NX)
pH (under 5% CO2)	7.25-7.54	"Same as predicate device" (Implies within 7.25-7.54 range)
Osmolality	260-270 mOsm/kg	"Same as predicate device" (Implies within 260-270 mOsm/kg range)
Formulation	39 ingredients (predicate device)	"Comparable to predicate device" (Modified; no HSA, adjusted concentrations)
1-cell Mouse Embryo Assay (MEA)	≥80% developed to the blastocyst stage at 96 hours	Met acceptance criteria (Implied by conclusion of substantial equivalence based on testing)
Human Sperm Survival Assay (HSSA)	≥70% of original motility at 24 hours	Met acceptance criteria (Implied by conclusion of substantial equivalence based on testing)
Endotoxin	≤0.25 EU/ml (LAL)	Met acceptance criteria (Implied by conclusion of substantial equivalence based on testing)
Sterility	No microbiological growth	Met acceptance criteria (Implied by conclusion of substantial equivalence based on testing)
Shelf-life	4 months (product stability meeting all listed criteria)	Confirmed over 4 months (real-time and accelerated studies)
In-use stability	4 weeks after opening/closing (storage at 2-8°C, meeting all listed criteria)	Confirmed over 4 weeks (stability testing)

The study supporting these claims are a series of non-clinical performance tests designed to demonstrate the substantial equivalence of the CSCM-NX to its predicate device.

Additional Information on the Study:

2. Sample size used for the test set and the data provenance:

Test Set Sample Size: The document does not specify exact sample sizes for the individual tests (MEA, HSSA, endotoxin, sterility, pH, osmolality). For the Mouse Embryo Assay, it mentions "One-cell mouse embryos were exposed to subject devices," indicating a biological sample rather than a human data set. For other tests, specific batch or replicate numbers are not provided.
Data Provenance: The studies were internal non-clinical performance tests conducted by Irvine Scientific. The data is prospective as it was generated specifically for the 510(k) submission. No country of origin for external data is mentioned, as the studies appear to be proprietary.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

This is a product performance study for a culture medium, not a diagnostic device relying on expert interpretation of results. Therefore, no experts were used to establish ground truth in the sense of clinical decision-making. The "ground truth" for these tests are objective, measurable laboratory parameters (e.g., pH, osmolality, blastocyst development rates, sperm motility percentages, endotoxin levels, sterility absence).

4. Adjudication method for the test set:

Not applicable. As described above, there is no expert interpretation or adjudication involved in determining the outcome of these objective laboratory tests. The results are quantitative measurements or observation of biological phenomena against predefined criteria.

5. If a multi-reader, multi-case (MRMC) comparative effectiveness study was done:

No, an MRMC comparative effectiveness study was not done. This type of study is relevant for diagnostic devices where human readers interpret medical images or data. The CSCM-NX is a culture medium, and its effectiveness is determined by objective laboratory assays, not by human interpretation of its "output" in a clinical setting. Therefore, there is no effect size presented for human readers improving with or without AI assistance.

6. If a standalone (i.e., algorithm only without human-in-the-loop performance) was done:

Not applicable. This device is not an algorithm or an AI system. It is a biological culture medium. Performance is assessed through specific biological and chemical assays.

7. The type of ground truth used:

The ground truth for this device's performance relies on objective, verifiable laboratory measurements and biological outcomes established through standardized assays. This includes:
- Chemical properties (pH, osmolality).
- Biological response (mouse embryo development to blastocyst, human sperm motility).
- Contaminant levels (endotoxin).
- Absence of microbial growth (sterility).
- These measurements are compared against pre-established acceptance criteria, which were likely derived from industry standards, historical performance of the predicate device, or biological necessity for successful embryo culture.

8. The sample size for the training set:

Not applicable. This device is a culture medium, not a machine learning model. Therefore, there is no "training set" in the context of algorithm development.

9. How the ground truth for the training set was established:

Not applicable. As there is no training set for an algorithm, there is no ground truth established for such a set.

Summary

{0}------------------------------------------------

Image /page/0/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, with a flowing, abstract design connecting them.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

June 8, 2017

Irvine Scientific Sales Co., Inc. Jayme Yamaguchi-Owens Regulatory Affairs Manager 2511 Daimler Street Santa Ana, CA 92705

Re: K170681

Trade/Device Name: Continuous Single Culture® -NX (CSCM-NX) Regulation Number: 21 CFR§ 884.6180 Regulation Name: Reproductive Media and Supplements Regulatory Class: II Product Code: MOL Dated: May 18, 2017 Received: May 23, 2017

Dear Jayme Yamaguchi-Owens:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{1}------------------------------------------------

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies.

You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely.

Image /page/1/Picture/10 description: The image shows the text "Benjamin R. Fisher -S" in a large, bold, sans-serif font. The text is black and is set against a white background. The letters are evenly spaced and the text is easy to read. The overall impression is clean and professional.

Benjamin R. Fisher, Ph.D. Director Division of Reproductive, Gastro-Renal, and Urological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known) K170681

Device Name

Continuous Single Culture®-NX (CSCM-NX)

Indications for Use (Describe)

The Continuous Single Culture®-NX (CSCM-NX) is intended for use as a culture medium for human gametes and embryos from fertilization through day 5/6 of development in vitro.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.

{3}------------------------------------------------

510(k) Summary

-General Information on Submitter

Submitter/Address:	Irvine Scientific Sales Co., Inc.2511 Daimler StreetSanta Ana, CA 92705Telephone: 800-437-5706Facsimile: 949-261-6522
Contact Person:	Jayme Yamaguchi-OwensRegulatory Affairs ManagerIrvine Scientific2511 Daimler StreetSanta Ana, CA 92705Tel: 949-261-7800 ext 254Fax: 949-261-6522Email: jfy@irvinesci.com

II. Date Prepared: June 6, 2017

III. General Information on Device

Device Name:	Continuous Single Culture®-NX (CSCM-NX)
Common Name:	Embryo Culture Media
Classification Name:	Reproductive Media and Supplements (21 CFR 884.6180)
Product code:	MQL (Media, Reproductive)
Regulatory Class:	II
IV. Predicate Device:	Continuous Single Culture Complete (K121572) manufactured by Irvine Scientific Sales Co., Inc. This

V. Description of the Device:

related recalls.

predicate device has not been subject to any design

This product is a single-use device supplied in a fill volume of 20 mL and 60 mL. It is aseptically filled into sterilized bottles and has a sterility assurance level (SAL) of 10° The product is tested for pH, osmolality, embryotoxicity, spermtoxicity, endotoxin, and sterility before lot release. The product has a four-month shelf-life and remains stable for four weeks after opening/closing of the bottle when it is stored at 2-8°C.

{4}------------------------------------------------

VI. Indication for Use:

The Continuous Single Culture®-NX (CSCM-NX) is intended for use as a culture medium for human gametes and embryos from fertilization through day 5/6 of development in vitro.

VII. Comparison of Intended Use and Technological Characteristics of Subject and Predicate Devices

Device & PredicateDevice(s):	K170681(subject device)	K121572(predicate device)
Indications for Use	Same as predicate device	Continuous Single Culture completeis intended for use as a culturemedium for human gametes andembryos from fertilization throughday 5/6 of development in vitro.
pH (under 5% CO2)	Same as predicate device	7.25-7.54
Osmolality	Same as predicate device	260-270 mOsm/kg
Formulation	Comparable to predicate device	39 ingredients

The subject and predicate devices have the same indication - culture of embryos from fertilization to blastulation. Therefore, they have the same intended use.

The subject and predicate devices have the same pH, osmolality and comparable formulations. Unlike the predicate device, the subject device does not contain human serum albumin (HSA), but needs addition of HSA before use. In addition, the concentrations of certain ingredients are modified in the subject device. The differences noted between the subject and predicate devices are minor and do not raise different questions of safety and effectiveness.

In addition to pH and osmolality, the acceptance criteria for other product characteristics of the subject device, including mouse embryo assay (MEA), human sperm survival assay (HSSA), endotoxin and sterility, are same to those of the predicate device.

VIII. Summary of Non-clinical Performance Testing

The following studies have been performed to support substantial equivalence to the predicate device:

pH ●
Osmolality
. Aseptic Processing Validation testing per ISO 13408-1:2008 and ISO 13408-2:2003
Sterility testing per USP <71> ●
Endotoxin testing per USP <85> ●
. Mouse embryo assay (MEA)

Continuous Single Culture®-NX (CSCM-NX)

{5}------------------------------------------------

One-cell mouse embryos were exposed to subject devices and cultured at 37°C in an atmosphere containing 5% CO2. The percent of embryos developed to the expanded blastocyst stage at 96 hours were assessed in comparison with the control group.

. Shelf-life studies (real-time and accelerated) were conducted to ensure that the following acceptance criteria for product characteristics are met at time zero and the end of shelf-life.
- pH See table above *
- - Osmolality - See table above
- - 1-cell MEA - ≥80% developed to the blastocyst stage at 96 hours
- - HSSA - ≥70% of original motility at 24 hours
- Endotoxin ≤0.25 EU/ml (LAL) *
- ★ Sterility - No microbiological growth
. Stability testing was conducted to ensure that acceptance criteria for the product specifications are met after repeated opening/closing of bottles for four (4) weeks if handled appropriately.

XI. Conclusion:

The subject and predicate devices have the same intended use. Although there is a difference in formulation between the subject and predicate devices, this difference does not raise different questions of safety or effectiveness. The performance data also demonstrate that the subject device is substantially equivalent to the predicate device.

Regulation Number and Section

§ 884.6180 Reproductive media and supplements.

(a)
Identification. Reproductive media and supplement are products that are used for assisted reproduction procedures. Media include liquid and powder versions of various substances that come in direct physical contact with human gametes or embryos (including water, acid solutions used to treat gametes or embryos, rinsing solutions, sperm separation media, supplements, or oil used to cover the media) for the purposes of preparation, maintenance, transfer or storage. Supplements are specific reagents added to media to enhance specific properties of the media (e.g., proteins, sera, antibiotics, etc.).(b)
Classification. Class II (special controls) (mouse embryo assay information, endotoxin testing, sterilization validation, design specifications, labeling requirements, biocompatibility testing, and clinical testing). The device, when it is phosphate-buffered saline used for washing, and short-term handling and manipulation of gametes and embryos; culture oil used as an overlay for culture media containing gametes and embryos; and water for assisted reproduction applications, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 884.9.